Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post earnings per share of $6.79 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $5.18 to $8.23. Regeneron Pharmaceuticals posted earnings of $6.84 per share in the same quarter last year, which would indicate a negative year over year growth rate of 0.7%. The firm is expected to report its next quarterly earnings report on Wednesday, February 5th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $23.75 per share for the current financial year, with EPS estimates ranging from $22.26 to $25.34. For the next year, analysts anticipate that the business will post earnings of $26.63 per share, with EPS estimates ranging from $23.33 to $30.55. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $1.54. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The business had revenue of $2.05 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the prior year, the business earned $5.87 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.2% compared to the same quarter last year.
Several brokerages have recently weighed in on REGN. Credit Suisse Group raised their price target on shares of Regeneron Pharmaceuticals from $310.00 to $340.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Cowen set a $349.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, October 8th. Robert W. Baird raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a research note on Wednesday, August 7th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $375.00 to $387.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $375.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $384.63.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $340.44, for a total value of $340,440.00. Following the completion of the sale, the director now owns 10,323 shares of the company’s stock, valued at approximately $3,514,362.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. Corporate insiders own 11.84% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Altfest L J & Co. Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $538,000. Bank of Nova Scotia boosted its stake in shares of Regeneron Pharmaceuticals by 25.4% in the 2nd quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock valued at $6,833,000 after purchasing an additional 4,420 shares in the last quarter. KBC Group NV boosted its stake in shares of Regeneron Pharmaceuticals by 25.6% in the 2nd quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock valued at $15,221,000 after purchasing an additional 9,912 shares in the last quarter. Calamos Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock valued at $3,728,000 after purchasing an additional 248 shares in the last quarter. Finally, Gargoyle Investment Advisor L.L.C. boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 2nd quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock valued at $478,000 after purchasing an additional 97 shares in the last quarter. 66.61% of the stock is owned by institutional investors.
NASDAQ REGN opened at $344.28 on Friday. The business has a 50 day simple moving average of $300.61 and a 200 day simple moving average of $304.38. Regeneron Pharmaceuticals has a 52-week low of $271.37 and a 52-week high of $442.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03. The stock has a market cap of $37.54 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 1.50 and a beta of 1.14.
Regeneron Pharmaceuticals announced that its board has approved a stock repurchase plan on Tuesday, November 5th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire up to 2.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: What is Put Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.